Zacks Investment Research upgraded shares of KemPharm (NASDAQ:KMPH) from a hold rating to a buy rating in a research note published on Wednesday morning. The firm currently has $7.50 target price on the specialty pharmaceutical company’s stock.
According to Zacks, “KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. “
KMPH has been the topic of several other research reports. ValuEngine upgraded shares of KemPharm from a sell rating to a hold rating in a report on Friday, February 2nd. Canaccord Genuity set a $11.00 target price on shares of KemPharm and gave the stock a buy rating in a research note on Friday, February 23rd. Oppenheimer set a $13.00 target price on shares of KemPharm and gave the stock a buy rating in a research note on Sunday, February 25th. Finally, Royal Bank of Canada set a $9.00 target price on shares of KemPharm and gave the stock a buy rating in a research note on Tuesday, January 16th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $9.70.
A hedge fund recently raised its stake in KemPharm stock. Alyeska Investment Group L.P. lifted its position in KemPharm Inc (NASDAQ:KMPH) by 1.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 992,338 shares of the specialty pharmaceutical company’s stock after acquiring an additional 17,721 shares during the quarter. Alyeska Investment Group L.P. owned approximately 6.77% of KemPharm worth $3,672,000 at the end of the most recent reporting period. Institutional investors own 36.56% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “KemPharm (KMPH) Upgraded by Zacks Investment Research to Buy” was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3296096/kempharm-kmph-upgraded-by-zacks-investment-research-to-buy.html.
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.